These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2847992)

  • 1. Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.
    Holoye PY; Carr DT; Dhingra HM; Glisson BS; Lee JS; Murphy WK; Umsawasdi T; Jeffries D
    Invest New Drugs; 1988 Sep; 6(3):217-8. PubMed ID: 2847992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study.
    Ettinger DS; Day R; Ferraro JA; Ruckdeschel JC; Woll JE; Creech RH; Vogl SE
    Am J Clin Oncol; 1983 Apr; 6(2):167-70. PubMed ID: 6299093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
    Dimery IW; Neidhart JA; McCarthy K; Krakoff IH; Hong WK
    Cancer Treat Rep; 1987 Apr; 71(4):425-6. PubMed ID: 3548960
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma.
    McMahon LJ; Jones SE; Durie BG; Salmon SE
    Cancer Lett; 1975 Nov; 1(2):97-102. PubMed ID: 65213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiazofurin: biological effects and clinical uses.
    Tricot G; Jayaram HN; Weber G; Hoffman R
    Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.
    Raghavan D; Bishop J; Sampson D; Grygiel J; Woods R; Coates A; Fox R
    Cancer Chemother Pharmacol; 1986; 16(2):160-4. PubMed ID: 3948303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of tiazofurin (NSC 286193) in treating disseminated tumor cells and micrometastases in mice.
    Lapis K; Pápay J; Paku S
    Oncology; 1990; 47(4):359-64. PubMed ID: 2367062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CCNU (NSC-79037) on bronchogenic carcinoma.
    Takita H; Brugarolas A
    J Natl Cancer Inst; 1973 Jan; 50(1):49-53. PubMed ID: 4348225
    [No Abstract]   [Full Text] [Related]  

  • 10. 2-beta-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases.
    Robins RK; Srivastava PC; Narayanan VL; Plowman J; Paull KD
    J Med Chem; 1982 Feb; 25(2):107-8. PubMed ID: 7057413
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
    Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.
    Osterlind K; Dombernowsky P; Sørensen PG; Hansen HH
    Cancer Treat Rep; 1981; 65(3-4):245-8. PubMed ID: 6263469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
    Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
    Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of bronchogenic carcinomas by a combination of cyclophosphamide, methotrexate, vincristin and bleomycin.
    Schaerer R; Sotto JJ; Wiget U; Perdrix A; Bensa JC; Ribaud P
    Eur J Cancer (1965); 1977; 13(4-5):425-8. PubMed ID: 68881
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.
    Melink TJ; Sarosy G; Hanauske AR; Phillips JL; Bayne JH; Grever MR; Jayaram HN; Von Hoff DD
    Sel Cancer Ther; 1990; 6(1):51-61. PubMed ID: 2343202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with vindesine and cisplatin for refractory small cell bronchogenic carcinoma.
    Chiuten DF; Carr DT; Dhingra HM; Murphy WK; Spitzer G; Umsawasdi T; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1986 Jun; 70(6):795-6. PubMed ID: 3015403
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.
    Presant CA; Hillinger S; Klahr C
    Cancer; 1980 Jan; 45(1):6-10. PubMed ID: 6243243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cis-Dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study.
    Dombernowsky P; Sörenson S; Aisner J; Hansen HH
    Cancer Treat Rep; 1979 Apr; 63(4):543-5. PubMed ID: 221119
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy of inoperable bronchogenic carcinoma.
    Behera D; Malik SK
    Indian J Chest Dis Allied Sci; 1985; 27(3):175-89. PubMed ID: 3017850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.